Home » Stocks » SRPT

Sarepta Therapeutics, Inc. (SRPT)

Stock Price: $153.33 USD 3.36 (2.24%)
Updated December 3, 4:00 PM EST - Market closed
After-hours: $155.00 +1.67 (1.09%) Dec 3, 7:25 PM

SRPT Stock Price Chart

Key Info

Market Cap 12.10B
Revenue (ttm) 495.07M
Net Income (ttm) -600.51M
Shares Out 78.50M
EPS (ttm) -7.81
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $153.33
Previous Close $149.97
Change ($) 3.36
Change (%) 2.24%
Day's Open 151.00
Day's Range 150.63 - 155.50
Day's Volume 698,296
52-Week Range 82.38 - 172.34

SRPT Stock News

Seeking Alpha - 1 day ago

Sarepta Therapeutics, Inc. (SRPT) Presents at Evercore ISI HealthCONx Conference - (Transcript)

GlobeNewsWire - 3 days ago

CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, ...

GlobeNewsWire - 1 week ago

CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management...

GlobeNewsWire - 1 week ago

-- Sarepta is h onored to be recognized for offering a range of benefits and work-life resources to employees and supporting the local community -- -- Rankings based on confidential survey inf...

Seeking Alpha - 3 weeks ago

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Credit Suisse 29th Annual Virtual Healthcare Conference (Transcript)

Other stocks mentioned: CS
Insider Monkey - 3 weeks ago

We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail i...

Zacks Investment Research - 3 weeks ago

Sarepta (SRPT) Q3 revenues increase year over year.

Seeking Alpha - 4 weeks ago

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q3 2020 Results - Earnings Call Transcript

Investors Business Daily - 4 weeks ago

Sarepta Therapeutics reported third-quarter losses of $1.42 per share on $121.4 million in sales late Thursday. But SRPT stock was flat in extended trades.

GlobeNewsWire - 4 weeks ago

-- Dosing with SRP-9001 commercial-process material to proceed following discussions with U.S. FDA -- -- Clinical d osing is expected to begin b efore the end of 2020 --

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management...

Investors Business Daily - 1 month ago

A Relative Strength Rating upgrade for Sarepta Therapeutics shows improving technical performance. The post Sarepta Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating appeared first ...

Zacks Investment Research - 1 month ago

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2020 financi...

GlobeNewsWire - 1 month ago

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- A premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences (“Bain Capital”), and RA Capital Ma...

Seeking Alpha - 1 month ago

Sarepta has a diversified portfolio of 43 programs including 27 gene therapy and 14 RNA programs. The pipeline is spread between discovery (21) and commercial (2) medicines.

Forbes - 2 months ago

Gene therapy - which aims to treat diseases by essentially inserting a gene into a patient’s cells rather than via drugs or surgery - was a hot trend in the biotech space, but investor interes...

Other stocks mentioned: QURE, RGNX, VYGR
CNBC Television - 2 months ago

Biotech analyst discusses her top stock picks: Biogen & Sarepta Therapeutics

The biotech index has been up nearly 38 percent since its March lows. Big movers include TG Therapeutics and Arena Pharmaceuticals. Alethia Young, Cantor Fitzgerald biotech analyst, joins 'Clo...

Other stocks mentioned: BIIB
GlobeNewsWire - 2 months ago

--Results demonstrate continued safety and tolerability of SRP-9001 in four participants with Duchenne -- --All four participants demonstrated improvements in NSAA scores compared to...

GlobeNewsWire - 2 months ago

-- Continued functional improvement s were observed at 18 months in the low - dose cohort --  -- First look at functional outcomes in high-dose cohort found improvements 6 months after...

Seeking Alpha - 2 months ago

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)

Other stocks mentioned: MS
Seeking Alpha - 2 months ago

Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 21 recipients of Ro...

GlobeNewsWire - 2 months ago

-- Webcast conference call to be held on Monday, Sept. 28, 2020 at 8:30 a.m. Eastern Time -- -- Additional poster presentations at WMS will highlight data from Sarepta’s RNA and gene therapy...

Seeking Alpha - 2 months ago

Sarepta Therapeutics, Inc. (SRPT) Presents at Robert W Baird Global Healthcare Broker Conference Call - (Transcript)

Investors Business Daily - 2 months ago

A request by the Food and Drug Administration that Sarepta Therapeutics provide for more data before Phase 3 trials start on a Duchenne muscular dystrophy treatment sent SRPT stock falling. Th...

Market Watch - 2 months ago

Shares of Sarepta Therapeutics Inc. SRPT, +1.17% were down 0.7% in premarket trading on Thursday, the day after the company said it had submitted a written response to the Food and Drug Admini...

GlobeNewsWire - 2 months ago

CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has complet...

Zacks Investment Research - 2 months ago

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior managem...

Zacks Investment Research - 3 months ago

Sarepta (SRPT) is seeking accelerated approval for exon 45 amenable DMD candidate, casimersen. Amondys 45 is likely to be the brand name for the candidate.

Investors Business Daily - 3 months ago

Sarepta Therapeutics on Tuesday announced that the FDA agreed to an accelerated approval process for its treatment for certain patients with Duchenne muscular dystrophy, lifting SRPT stock. Th...

GlobeNewsWire - 3 months ago

-- FDA grants Priority Review Status and sets regulatory action date for February 25, 2021 -- -- FDA has indicated it does not currently plan to hold an advisory committee meeting to discuss ...

GlobeNewsWire - 3 months ago

CAMBRIDGE, Mass. and GAINESVILLE, Fla., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, and the Univers...

Zacks Investment Research - 3 months ago

Sarepta (SRPT) Q2 revenues increase year over year.

Seeking Alpha - 3 months ago

Sarepta Therapeutics' (SRPT) CEO Doug Ingram on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -6.63% and 22.25%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the s...

GlobeNewsWire - 3 months ago

– Net product sales of $111.3 million, an 18% increase over same quarter of prior year –

Zacks Investment Research - 4 months ago

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2020 fina...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food a...

GlobeNewsWire - 4 months ago

CAMBRIDGE, Mass., July 15, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the launch of Rare L...

GlobeNewsWire - 5 months ago

-- Exclusive worldwide license enables Sarepta to develop and promote imlifidase as a pre-treatment for gene therapy in Duchenne and Limb-girdle muscular dystrophy patients who have pre-existi...

GlobeNewsWire - 5 months ago

CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the retirement of Sa...

Zacks Investment Research - 5 months ago

Sarepta (SRPT) is seeking accelerated approval for its third exon-skipping therapy, casimersen, for DMD patients.

GlobeNewsWire - 5 months ago

-- Casimersen is designed for the treatment of exon 45 amenable patients, approximately eight percent of patients with Duchenne -- -- Casimersen is the third exon-skipping medicine using the...

CNBC Television - 5 months ago

Time to double down on biotech?

Chris Verrone, Strategas, on the biotech stocks. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen Finerman and Steve Grasso.

Other stocks mentioned: ABBV, IBB
Seeking Alpha - 5 months ago

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Bank of America Napa Healthcare Conference (Transcript)

Other stocks mentioned: BAC
GuruFocus - 5 months ago

On the heels of research deals with two small biotechs, shares of Sarepta Therapeutics Inc.

Zacks Investment Research - 5 months ago

Sarepta (SRPT) and Codiak BioSciences sign agreement to develop potential gene therapies targeting neuromuscular indications using Codiak's engineered exosomes.

About SRPT

Sarepta Therapeutics, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities approaches for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skip... [Read more...]

Industry
Biotechnology
IPO Date
Jun 3, 1997
CEO
Douglas Ingram
Employees
743
Stock Exchange
NASDAQ
Ticker Symbol
SRPT
Full Company Profile

Financial Performance

In 2019, SRPT's revenue was $380.83 million, an increase of 26.51% compared to the previous year's $301.03 million. Losses were -$715.08 million, 97.6% more than in 2018.

Financial Statements

Analyst Forecasts

According to 24 analysts, the average rating for SRPT stock is "Buy." The 12-month stock price forecast is 189.68, which is an increase of 23.71% from the latest price.

Price Target
$189.68
(23.71% upside)
Analyst Consensus: Buy